Clinical trial led by Dr. Mollie Carruthers & team found that weekly treatment with obexelimab significantly reduced disease flares, increased remission rates, & lowered the need for steroid treatment among people with IgG4-related disease. See #infographic below for further study details.

What should the future of inflammatory arthritis care look like? Our study presented at #EULAR2026 by Dr. @susanbartlett.bsky.social led in collaboration with Dr. @dlacaille.bsky.social is guiding the development of #FlexCAre, a new care model that meets the diverse needs of people with arthritis.

At #EULAR2026, Dr. @lihieder.bsky.social draws attention to hormonal influences on psoriatic arthritis by showing that disease activity, including joint pain & swelling, is worse during the #perimenopausal period for women with psoriatic arthritis. #PsoriaticArthritis #WomensHealth #Rheumatology

Great to see Arthritis Research Canada scientist Dr. Denislav Orlinov presenting at #EULAR2026 and participating in some great conversations with colleagues. We are proud to see our team sharing their work with the global rheumatology community! #Rheumatology #ArthritisResearch

First debate from #EULAR26 🫯 Should polymyalgia rheumatica be managed by GPs or rheumatologist ❓ After a first round of talks, 80% of the audience is convinced that rheumatologist should managed PMR. 📊

PhD student M Beydon, supervised by Dr. Tubach & our Scientific Director Dr. @dlacaille.bsky.social led a study drawing attention to the common use of glucocorticosteroids for prolonged periods for giant cell arteritis & how this increases the risk of infections, heart diseases, fractures & death.

Scientist Dr. @natalie-mccor.bsky.social explored the impact of weight loss drugs in people with rheumatic diseases. Both semaglutide & tirzepatide led to meaningful weight loss, more so with tirzepatide and in people without diabetes. Ongoing work is evaluating impact on disease outcomes #EULAR2026

We are very excited because our team is currently at @eular.org 2026 in London, England! Be sure to check out our research summaries of our conference presentations for Day 1 of the conference: www.arthritisresearch.ca/eular-europe...

International recommendations are encouraging people with arthritis to move more. The updated @eular.org recommendations reinforce that physical activity is safe, beneficial, and should be a part of arthritis care. Read the full paper here🔗: www.sciencedirect.com/science/arti...

Our team is comprised of scientists from across Canada 🇨🇦, spanning multiple disciplines. Pictured here: our rare disease registry team meeting in Halifax. It was such a valuable opportunity to connect in person. Moments like this remind us how powerful national collaboration is!

Pregnant patients with rheumatic diseases face higher preeclampsia risk. In our study from a Canadian registry, most met criteria for low-dose aspirin (ASA). While outcomes were similar between groups, findings support low-dose aspirin use in high-risk patients per guidelines. #Rheumatology #OBGYN

PhD student Nicole Andersen & scientist Dr. Deborah Da Costa presenting their study that looked at cannabis use in people with inflammatory arthritis enrolled in testing an intervention for insomnia. 🔑Key findings in ⬇️ reply.

Pictured here is Arthritis Research Canada scientist Dr. May Choi and her team at the 2026 CRA Annual Scientific Meeting!

We are excited to share executive summaries of the research abstracts that Arthritis Research Canada scientists & trainees are presenting at the 2026 Canadian Rheumatology Association Scientific Meeting. Check out our presentations here: ow.ly/9ckM50YKJiJ

Congratulations to Dr. Raheem Kherani for being recognized with a Practice Reflection Award from the Canadian Rheumatology Association for leading the development of a mini practice audit tool with UBC rheumatology resident Dr. Madelaine Beckett that allows rheumatologists to review & improve care!

Our Scientific Director Dr. @dlacaille.bsky.social & scientist Dr. Cheryl Barnabe are at the 2026 CRA Annual Scientific Meeting in Halifax this week. Dr. Cheryl Barnabe was honoured with a Distinguished Investigator award for her research & work providing arthritis care in Indigenous communities.

Our new study finds HCQ retinopathy risk increases with duration and dose. Pooled prevalence is 5.1%, and cumulative incidence reaches 5.6% by 15 years. Higher risk: >5 mg/kg/day, CKD, female sex, Asian ethnicity. This supports dose optimization and targeted SD-OCT screening.

🧪📚 Our team's scoping review of tsDMARD use in pregnancy: From 6,712 records, only 8 studies met criteria (mostly case reports; n=1–116). Evidence was available on tofacitinib, baricitinib & upadacitinib; none on apremilast.

Stenotic large vessel vasculitis is a rare and largely unknown subtype of giant cell arteritis (GCA). Retrospective study of 3,149 patients evaluated long-term outcome and prognosis of GCA with stenotic LVV Arthritis & Rheumatology acrjournals.onlinelibrary.wiley.com/doi/10.1002/...

In a nationwide cohort, spondyloarthritis diagnosis was associated with inflammatory bowel disease preceding & following its diagnosis. Findings also demonstrated temporal variability & highlighted clinical variables associated with SpA in IBD A&R doi.org/10.1002/art.... @predictibd.bsky.social

Randomised controlled trial led by @lli-1.bsky.social shows counselling combined with self-monitoring tools can help people with #RheumatoidArthritis manage their condition better. It can also improve symptoms like fatigue & mood. 🔗Link to paper: pubmed.ncbi.nlm.nih.gov/38152927/

ILD trajectories differ across IIM subsets. In a BC cohort (n=111), our team found that PmPPF occurred in 13.5%, mainly in anti-MDA5+ DM & antisynthetase syndrome, and was absent in scleromyositis. PmPPF associated with ↑ active disease, ↑ rapidly progressive ILD & ↑ transplant (20% vs 1.3%).

New population-based study (n=229,300 T2D): GLP-1RAs & SGLT2is showed no ↑ or ↓ in overall autoimmune rheumatic disease risk vs. DPP4is. But SGLT2is were linked to ~50% ↓ risk of systemic ARDs. Study led by Dr. @derinkaracabeyli.bsky.social. See infographic 👇

JointHealth™ express - #ArthritisAtHome 306 – A discussion on rheum-oncology & artificial intelligence in rheumatology. Watch now: arthritisathome.jointhealth.org?p=6743 #cancer #arthritis #AI @arthritispower.bsky.social @arthritistrainees.bsky.social @schroeder-uhn.bsky.social @achronicvoice.com

Takin hydroxychloroquine as prescribed- reduces hospitalizations snd save dollars!! - as simple as that!!

What is the impact of GLP-1RA & SGLT2i use on risk of developing autoimmune rheumatic diseases (ARD)? Data from a Canadian cohort of adults w/ type 2 diabetes showed SGLT2i use was assoc w/ lower risk of systemic ARDs, but neither GLP-1RA nor SGLT2i treatment was assoc w/ lower non-systemic ARD risk

Our new study finds that early antimalarial adherence (PDC≥0.90) in incident RA/SLE is associated with lower acute care use & costs (BC cohort, 1997–2022; n=25,247): 11% ↓ admissions (RR 0.89), 21% ↓ hosp days (RR 0.79), −$550 CAD costs. Robust to sensitivity analyses. See graphical abstract below.

JointHealth™ express - Now Launching: JointHealth™ Education – #Arthritis and #MentalHealth. Click here to begin the course: bit.ly/JointHealthE... Thank you Dr. Susan Bartlett for your help with this course! 🥰 @schroeder-uhn.bsky.social @arthritistrainees.bsky.social @arthritispower.bsky.social

New Canadian living guidelines address an important gap in cancer care: managing immune checkpoint inhibitors in patients with pre-existing inflammatory arthritis & systemic autoimmune rheumatic diseases. See GRADE-based, disease-specific recommendations in the embedded infographic.

Looking to get active with #arthritis? Yoga might be a great place to start!